18 results on '"Williams, Nerissa T."'
Search Results
2. Targeting glutamine metabolism improves sarcoma response to radiation therapy in vivo
- Author
-
Patel, Rutulkumar, Cooper, Daniel E., Kadakia, Kushal T., Allen, Annamarie, Duan, Likun, Luo, Lixia, Williams, Nerissa T., Liu, Xiaojing, Locasale, Jason W., and Kirsch, David G.
- Published
- 2024
- Full Text
- View/download PDF
3. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma
- Author
-
Odhiambo, Diana A., Pittman, Allison N., Rickard, Ashlyn G., Castillo, Rico J., Bassil, Alex M., Chen, Joshua, Ravotti, Madison L., Xu, Eric S., Himes, Jonathan E., Daniel, Andrea R., Watts, Tammara L., Williams, Nerissa T., Luo, Lixia, Kirsch, David G., and Mowery, Yvonne M.
- Published
- 2024
- Full Text
- View/download PDF
4. Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus
- Author
-
Floyd, Warren, Pierpoint, Matthew, Su, Chang, Patel, Rutulkumar, Luo, Lixia, Deland, Katherine, Wisdom, Amy J., Zhu, Daniel, Ma, Yan, DeWitt, Suzanne Bartholf, Williams, Nerissa T., Lazarides, Alexander L., Somarelli, Jason A., Corcoran, David L., Eward, William C., Cardona, Diana M., and Kirsch, David G.
- Subjects
Sarcoma -- Genetic aspects -- Care and treatment -- Development and progression ,Cyclic guanylic acid -- Physiological aspects -- Health aspects ,Radiotherapy -- Usage ,Health care industry - Abstract
ATRX is one of the most frequently altered genes in solid tumors, and mutation is especially frequent in soft tissue sarcomas. However, the role of ATRX in tumor development and response to cancer therapies remains poorly understood. Here, we developed a primary mouse model of soft tissue sarcoma and showed that Atrx-deleted tumors were more sensitive to radiation therapy and to oncolytic herpesvirus. In the absence of Atrx, irradiated sarcomas had increased persistent DNA damage, telomere dysfunction, and mitotic catastrophe. Our work also showed that Atrx deletion resulted in downregulation of the CGAS/STING signaling pathway at multiple points in the pathway and was not driven by mutations or transcriptional downregulation of the CGAS/STING pathway components. We found that both human and mouse models of Atrx-deleted sarcoma had a reduced adaptive immune response, markedly impaired CGAS/STING signaling, and increased sensitivity to TVEC, an oncolytic herpesvirus that is currently FDA approved for the treatment of aggressive melanomas. Translation of these results to patients with ATRX-mutant cancers could enable genomically guided cancer therapy approaches to improve patient outcomes., Introduction ATRX, or [alpha]-thalassemia/mental retardation, X-linked, is a chromatin remodeling protein and tumor suppressor, with mutations or copy number alterations occurring in approximately 6% of the more than 65,163 tumors [...]
- Published
- 2023
- Full Text
- View/download PDF
5. Radiosensitizing the Vasculature of Primary Brainstem Gliomas Fails to Improve Tumor Response to Radiation Therapy
- Author
-
Deland, Katherine, Mercer, Joshua S., Crabtree, Donna M., Guerra Garcia, Maria E., Reinsvold, Michael, Campos, Lorraine Da Silva, Williams, Nerissa T., Luo, Lixia, Ma, Yan, Reitman, Zachary J., Becher, Oren J., and Kirsch, David G.
- Published
- 2022
- Full Text
- View/download PDF
6. Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy
- Author
-
Wisdom, Amy J., Mowery, Yvonne M., Hong, Cierra S., Himes, Jonathon E., Nabet, Barzin Y., Qin, Xiaodi, Zhang, Dadong, Chen, Lan, Fradin, Hélène, Patel, Rutulkumar, Bassil, Alex M., Muise, Eric S., King, Daniel A., Xu, Eric S., Carpenter, David J., Kent, Collin L., Smythe, Kimberly S., Williams, Nerissa T., Luo, Lixia, Ma, Yan, Alizadeh, Ash A., Owzar, Kouros, Diehn, Maximilian, Bradley, Todd, and Kirsch, David G.
- Published
- 2020
- Full Text
- View/download PDF
7. Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma.
- Author
-
Tu, Kevin J., Stewart, Connor E., Williams, Nerissa T., Ma, Yan, Luo, Lixia, Ghosh, Debosir, Weidenhammer, Loren B., Floyd, Scott R., Fan, Yi, Kirsch, David G., Oldham, Mark, and Reitman, Zachary J.
- Subjects
MICE ,LABORATORY mice ,RADIATION doses ,MEDULLOBLASTOMA ,ANIMAL disease models ,TRANSGENIC mice ,RADIOTHERAPY safety - Abstract
Medulloblastoma is the most common malignant brain tumor of children. Although standard of care radiotherapy for pediatric medulloblastoma (PM) can lead to long-term remission or cure in many patients, it can also cause life-long cognitive impairment and other adverse effects. The pathophysiological mechanisms involved in radiation-induced cerebral damage are incompletely understood, and their elucidation may lead to interventions that mitigate radiation toxicity. To explore the mechanisms of radiation-induced cerebral damage, transgenic mouse models of PM and non-tumor-bearing controls were exposed to radiation doses that ranged from 0 to 30 Gy. Between 0–20 Gy, a significant dose-dependent reduction in tumor-associated hydrocephalus and increase in overall survival were observed. However, at 30 Gy, hydrocephalus incidence increased and median overall survival fell to near-untreated levels. Immunohistochemistry revealed that both tumor-bearing and non-tumor-bearing mice treated with 30 Gy of radiation had significantly more reactive astrocytes and microvascular damage compared to untreated controls. This effect was persistent across mice that were given 1 and 2 weeks of recovery time after irradiation. Our data suggest that radiation therapy promotes neural death by inducing long-term neuroinflammation in PM, suggesting radiation delivery methods that limit inflammation may be effective at widening the therapeutic window of radiation therapy in PM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Radiation-induced bone loss in mice is ameliorated by inhibition of HIF-2α in skeletal progenitor cells.
- Author
-
Guo, Wendi, Hoque, Jiaul, Garcia Garcia, Carolina J., Spiller, Kassandra V., Leinroth, Abigail P., Puviindran, Vijitha, Potnis, Cahil K., Gunn, Kiana A., Newman, Hunter, Ishikawa, Koji, Fujimoto, Tara N., Neill, Denae W., Delahoussaye, Abagail M., Williams, Nerissa T., Kirsch, David G., Hilton, Matthew J., Varghese, Shyni, Taniguchi, Cullen M., and Wu, Colleen
- Subjects
LEPTIN ,PROGENITOR cells ,TOTAL body irradiation ,MICE ,HYPOXIA-inducible factors ,RADIATION exposure - Abstract
Radiotherapy remains a common treatment modality for cancer despite skeletal complications. However, there are currently no effective treatments for radiation-induced bone loss, and the consequences of radiotherapy on skeletal progenitor cell (SPC) survival and function remain unclear. After radiation, leptin receptor–expressing cells, which include a population of SPCs, become localized to hypoxic regions of the bone and stabilize the transcription factor hypoxia-inducible factor-2α (HIF-2α), thus suggesting a role for HIF-2α in the skeletal response to radiation. Here, we conditionally knocked out HIF-2α in leptin receptor–expressing cells and their descendants in mice. Radiation therapy in littermate control mice reduced bone mass; however, HIF-2α conditional knockout mice maintained bone mass comparable to nonirradiated control animals. HIF-2α negatively regulated the number of SPCs, bone formation, and bone mineralization. To test whether blocking HIF-2α pharmacologically could reduce bone loss during radiation, we administered a selective HIF-2α inhibitor called PT2399 (a structural analog of which was recently FDA-approved) to wild-type mice before radiation exposure. Pharmacological inhibition of HIF-2α was sufficient to prevent radiation-induced bone loss in a single-limb irradiation mouse model. Given that ~90% of patients who receive a HIF-2α inhibitor develop anemia because of off-target effects, we developed a bone-targeting nanocarrier formulation to deliver the HIF-2α inhibitor to mouse bone, to increase on-target efficacy and reduce off-target toxicities. Nanocarrier-loaded PT2399 prevented radiation-induced bone loss in mice while reducing drug accumulation in the kidney. Targeted inhibition of HIF-2α may represent a therapeutic approach for protecting bone during radiation therapy. Editor's summary: Radiotherapy frequently leads to bone loss. Here, Guo and colleagues explored the role of hypoxia signaling through HIF-2α in skeletal progenitor cells as a negative regulator of bone mass after radiotherapy in mice. Selective knockout of HIF-2α in leptin receptor-expressing skeletal progenitor cells rescued mice from decreased bone mass after total body irradiation. Pharmacologic inhibition of HIF-2α improved bone integrity; however, systemic treatment caused off-target effects. Therefore, a bone-targeting nanocarrier was developed to deliver localized HIF-2α inhibition, which alleviated radiation-induced bone loss without systemic off-target effects. This represents a promising targeted strategy that awaits further clinical validation. —Molly Ogle [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Tumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models
- Author
-
Deland, Katherine, Starr, Bryce F., Mercer, Joshua S., Byemerwa, Jovita, Crabtree, Donna M., Williams, Nerissa T., Luo, Lixia, Ma, Yan, Chen, Mark, Becher, Oren J., and Kirsch, David G.
- Subjects
Gene mutations -- Health aspects ,Gliomas -- Genetic aspects -- Development and progression -- Care and treatment ,Genotype -- Health aspects ,Radiotherapy -- Methods -- Patient outcomes ,Health care industry - Abstract
Diffuse intrinsic pontine glioma (DIPG) kills more children than any other type of brain tumor. Despite clinical trials testing many chemotherapeutic agents, palliative radiotherapy remains the standard treatment. Here, we utilized Cre/loxP technology to show that deleting Ataxia telangiectasia mutated (Atm) in primary mouse models of DIPG can enhance tumor radiosensitivity. Genetic deletion of Atm improved survival of mice with p53-deficient but not p53 wild-type gliomas after radiotherapy. Similar to patients with DIPG, mice with p53 wild-type tumors had improved survival after radiotherapy independent of Atm deletion. Primary p53 wild-type tumor cell lines induced proapoptotic genes after radiation and repressed the NRF2 target, NAD(P)H quinone dehydrogenase 1 (Nqo1). Tumors lacking p53 and Ink4a/Arf expressed the highest level of Nqo1 and were most resistant to radiation, but deletion of Atm enhanced the radiation response. These results suggest that tumor genotype may determine whether inhibition of ATM during radiotherapy will be an effective clinical approach to treat DIPGs., Introduction Diffuse intrinsic pontine glioma (DIPG), also referred to as highgrade brainstem glioma, is an incurable cancer that originates in the pons and occurs primarily in children. Focal radiation therapy [...]
- Published
- 2021
- Full Text
- View/download PDF
10. The Effect of Atm Loss on Radiosensitivity of a Primary Mouse Model of Pten -Deleted Brainstem Glioma.
- Author
-
Stewart, Connor E., Guerra-García, María E., Luo, Lixia, Williams, Nerissa T., Ma, Yan, Regal, Joshua A., Ghosh, Debosir, Sansone, Patrick, Oldham, Mark, Deland, Katherine, Becher, Oren J., Kirsch, David G., and Reitman, Zachary J.
- Subjects
BIOLOGICAL models ,PROTEIN kinases ,GENETIC mutation ,ANIMAL experimentation ,PHOSPHOTRANSFERASES ,GLIOMAS ,TUMORS in children ,RADIATION-sensitizing agents ,GENETIC techniques ,DNA damage ,BRAIN stem ,MICE ,PHYSIOLOGICAL effects of radiation - Published
- 2022
- Full Text
- View/download PDF
11. The p53 Transactivation Domain 1-Dependent Response to Acute DNA Damage in Endothelial Cells Protects against Radiation-Induced Cardiac Injury.
- Author
-
Kuo, Hsuan-Cheng, Luo, Lixia, Ma, Yan, Williams, Nerissa T., da Silva Campos, Lorraine, Attardi, Laura D., Lee, Chang-Lung, and Kirsch, David G.
- Subjects
HEART injuries ,DNA damage ,P53 antioncogene ,HEART cells ,IONIZING radiation ,RADIATION tolerance ,ENDOTHELIAL cells ,P53 protein - Abstract
Thoracic radiation therapy can cause endothelial injury in the heart, leading to cardiac dysfunction and heart failure. Although it has been demonstrated that the tumor suppressor p53 functions in endothelial cells to prevent the development of radiation-induced myocardial injury, the key mechanism(s) by which p53 regulates the radiosensitivity of cardiac endothelial cells is not completely understood. Here, we utilized genetically engineered mice that express mutations in p53 transactivation domain 1 (TAD1) (p53
25,26 ) or mutations in p53 TAD1 and TAD2 (p5325,26,53,54 ) specifically in endothelial cells to study the p53 transcriptional program that protects cardiac endothelial cells from ionizing radiation in vivo. p5325,26,53,54 loses the ability to drive transactivation of p53 target genes after irradiation while p5325,26 can induce transcription of a group of non-canonical p53 target genes, but not the majority of classic radiation-induced p53 targets critical for p53-mediated cell cycle arrest and apoptosis. After 12 Gy whole-heart irradiation, we found that both p5325,26 and p5325,26,53,54 sensitized mice to radiation-induced cardiac injury, in contrast to wild-type p53. Histopathological examination suggested that mutation of TAD1 contributes to myocardial necrosis after whole-heart irradiation, while mutation of both TAD1 and TAD2 abolishes the ability of p53 to prevent radiation-induced heart disease. Taken together, our results show that the transcriptional program downstream of p53 TAD1, which activates the acute DNA damage response after irradiation, is necessary to protect cardiac endothelial cells from radiation injury in vivo. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
12. Enhancing radiotherapy response via intratumoral injection of a TLR9 agonist in autochthonous murine sarcomas.
- Author
-
Su C, Kent CL, Pierpoint M, Floyd W, Luo L, Williams NT, Ma Y, Peng B, Lazarides AL, Subramanian A, Himes JE, Perez VM, Hernansaiz-Ballesteros RD, Roche KE, Modliszewski JL, Selitsky SR, Shinohara ML, Wisdom AJ, Moding EJ, Mowery YM, and Kirsch DG
- Subjects
- Animals, Mice, Sarcoma radiotherapy, Sarcoma therapy, Sarcoma pathology, Injections, Intralesional, CRISPR-Cas Systems, Sarcoma, Experimental pathology, Sarcoma, Experimental radiotherapy, Female, Toll-Like Receptor 9 agonists, Oligodeoxyribonucleotides pharmacology, Oligodeoxyribonucleotides administration & dosage, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes drug effects
- Abstract
Radiation therapy (RT) is frequently used to treat cancers, including soft-tissue sarcomas. Prior studies established that the toll-like receptor 9 (TLR9) agonist cytosine-phosphate-guanine oligodeoxynucleotide (CpG) enhances the response to RT in transplanted tumors, but the mechanisms of this enhancement remain unclear. Here, we used CRISPR/Cas9 and the chemical carcinogen 3-methylcholanthrene (MCA) to generate autochthonous soft-tissue sarcomas with high tumor mutation burden. Treatment with a single fraction of 20 Gy RT and 2 doses of CpG significantly enhanced tumor response, which was abrogated by genetic or immunodepletion of CD8+ T cells. To characterize the immune response to CpG+RT, we performed bulk RNA-Seq, single-cell RNA-Seq, and mass cytometry. Sarcomas treated with 20 Gy and CpG demonstrated increased CD8 T cells expressing markers associated with activation and proliferation, such as Granzyme B, Ki-67, and IFN-γ. CpG+RT also upregulated antigen presentation pathways on myeloid cells. Furthermore, in sarcomas treated with CpG+RT, TCR clonality analysis suggests an increase in clonal T cell dominance. Collectively, these findings demonstrate that CpG+RT significantly delays tumor growth in a CD8 T cell-dependent manner. These results provide a strong rationale for clinical trials evaluating CpG or other TLR9 agonists with RT in patients with soft-tissue sarcoma.
- Published
- 2024
- Full Text
- View/download PDF
13. Temporary Knockdown of p53 During Focal Limb Irradiation Increases the Development of Sarcomas.
- Author
-
Daniel AR, Su C, Williams NT, Li Z, Huang J, Lopez O, Luo L, Ma Y, Campos LDS, Selitsky SR, Modliszewski JL, Liu S, Hernansaiz-Ballesteros R, Mowery YM, Cardona DM, Lee CL, and Kirsch DG
- Subjects
- Humans, Mice, Animals, Tumor Suppressor Protein p53 genetics, Cell Cycle, DNA Damage, Sarcoma genetics, Radiation Injuries
- Abstract
Approximately half of patients with cancer receive radiotherapy and, as cancer survivorship increases, the low rate of radiation-associated sarcomas is rising. Pharmacologic inhibition of p53 has been proposed as an approach to ameliorate acute injury of normal tissues from genotoxic therapies, but how this might impact the risk of therapy-induced cancer and normal tissue injuries remains unclear. We utilized mice that express a doxycycline (dox)-inducible p53 short hairpin RNA to reduce Trp53 expression temporarily during irradiation. Mice were placed on a dox diet 10 days prior to receiving 30 or 40 Gy hind limb irradiation in a single fraction and then returned to normal chow. Mice were examined weekly for sarcoma development and scored for radiation-induced normal tissue injuries. Radiation-induced sarcomas were subjected to RNA sequencing. Following single high-dose irradiation, 21% of animals with temporary p53 knockdown during irradiation developed a sarcoma in the radiation field compared with 2% of control animals. Following high-dose irradiation, p53 knockdown preserves muscle stem cells, and increases sarcoma development. Mice with severe acute radiation-induced injuries exhibit an increased risk of developing late persistent wounds, which were associated with sarcomagenesis. RNA sequencing revealed radiation-induced sarcomas upregulate genes related to translation, epithelial-mesenchymal transition (EMT), inflammation, and the cell cycle. Comparison of the transcriptomes of human and mouse sarcomas that arose in irradiated tissues revealed regulation of common gene programs, including elevated EMT pathway gene expression. These results suggest that blocking p53 during radiotherapy could minimize acute toxicity while exacerbating late effects including second cancers., Significance: Strategies to prevent or mitigate acute radiation toxicities include pharmacologic inhibition of p53 and other cell death pathways. Our data show that temporarily reducing p53 during irradiation increases late effects including sarcomagenesis., (© 2023 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
14. Ataxia-telangiectasia mutated ( Atm ) disruption sensitizes spatially-directed H3.3K27M/TP53 diffuse midline gliomas to radiation therapy.
- Author
-
Mangoli A, Wu S, Liu HQ, Aksu M, Jain V, Foreman BE, Regal JA, Weidenhammer LB, Stewart CE, Guerra Garcia ME, Hocke E, Abramson K, Williams NT, Luo L, Deland K, Attardi L, Abe K, Hashizume R, Ashley DM, Becher OJ, Kirsch DG, Gregory SG, and Reitman ZJ
- Abstract
Diffuse midline gliomas (DMGs) are lethal brain tumors characterized by p53-inactivating mutations and oncohistone H3.3K27M mutations that rewire the cellular response to genotoxic stress, which presents therapeutic opportunities. We used RCAS/tv-a retroviruses and Cre recombinase to inactivate p53 and induce K27M in the native H3f3a allele in a lineage- and spatially-directed manner, yielding primary mouse DMGs. Genetic or pharmacologic disruption of the DNA damage response kinase Ataxia-telangiectasia mutated (ATM) enhanced the efficacy of focal brain irradiation, extending mouse survival. This finding suggests that targeting ATM will enhance the efficacy of radiation therapy for p53-mutant DMG but not p53-wildtype DMG. We used spatial in situ transcriptomics and an allelic series of primary murine DMG models with different p53 mutations to identify transactivation-independent p53 activity as a key mediator of such radiosensitivity. These studies deeply profile a genetically faithful and versatile model of a lethal brain tumor to identify resistance mechanisms for a therapeutic strategy currently in clinical trials.
- Published
- 2023
- Full Text
- View/download PDF
15. Inducing primary brainstem gliomas in genetically engineered mice using RCAS/TVA retroviruses and Cre/loxP recombination.
- Author
-
Weidenhammer LB, Liu HQ, Luo L, Williams NT, Deland K, Kirsch DG, and Reitman ZJ
- Subjects
- Mice, Animals, Retroviridae genetics, Recombination, Genetic, Brain Stem Neoplasms genetics, Brain Stem Neoplasms therapy, Glioma genetics, Glioma therapy
- Abstract
Genetically engineered mice are commonly used to model brainstem gliomas in pre-clinical research. One technique for inducing primary tumors in these genetically engineered mice involves delivering viral vectors containing the code for gene-editing proteins. We present a protocol for generating primary brainstem gliomas using the RCAS-TVA retroviral delivery system and the Cre/loxP gene editing system. We describe steps for transfecting and harvesting chicken fibroblast cells, intracranially injecting cells into mice, imaging primary tumors, and treating primary tumors with focal, image-guided brain irradiation. For complete details on the use and execution of this protocol, please refer to Deland et al. (2021).
1 ., Competing Interests: Declaration of interests D.G.K. is a cofounder of and stockholder in XRAD Therapeutics, which is developing radiosensitizers. D.G.K. is a member of the scientific advisory board and owns stock in Lumicell Inc, a company commercializing intraoperative imaging technology. None of these affiliations represents a conflict of interest with respect to the work described in this manuscript. D.G.K. is a coinventor on a patent for a handheld imaging device and is a coinventor on a patent for radiosensitizers. XRAD Therapeutics, Merck, Bristol Myers Squibb, and Varian Medical Systems provide research support to DGK, but this did not support the research described in this manuscript. Z.J.R. receives honoraria from Oakstone publishing and Eisai Pharmaceuticals for educational seminars. Z.J.R. receives royalties for intellectual property that is managed by Duke Office of Licensing and Ventures which has been licensed to Genetron Health. These sources did not support the research described in this manuscript., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
16. Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma.
- Author
-
Patel R, Mowery YM, Qi Y, Bassil AM, Holbrook M, Xu ES, Hong CS, Himes JE, Williams NT, Everitt J, Ma Y, Luo L, Selitsky SR, Modliszewski JL, Gao J, Jung SH, Kirsch DG, and Badea CT
- Subjects
- Mice, Animals, Neoadjuvant Therapy, Tumor Suppressor Protein p53 genetics, Progression-Free Survival, Disease-Free Survival, Retrospective Studies, Radiotherapy, Adjuvant, Neoplasm Recurrence, Local pathology, Sarcoma radiotherapy, Soft Tissue Neoplasms pathology, Soft Tissue Neoplasms surgery
- Abstract
This study aims to investigate whether adding neoadjuvant radiotherapy (RT), anti-programmed cell death protein-1 (PD-1) antibody (anti-PD-1), or RT + anti-PD-1 to surgical resection improves disease-free survival for mice with soft tissue sarcomas (STS). We generated a high mutational load primary mouse model of STS by intramuscular injection of adenovirus expressing Cas9 and guide RNA targeting Trp53 and intramuscular injection of 3-methylcholanthrene (MCA) into the gastrocnemius muscle of wild-type mice (p53/MCA model). We randomized tumor-bearing mice to receive isotype control or anti-PD-1 antibody with or without radiotherapy (20 Gy), followed by hind limb amputation. We used micro-CT to detect lung metastases with high spatial resolution, which was confirmed by histology. We investigated whether sarcoma metastasis was regulated by immunosurveillance by lymphocytes or tumor cell-intrinsic mechanisms. Compared with surgery with isotype control antibody, the combination of anti-PD-1, radiotherapy, and surgery improved local recurrence-free survival (P = 0.035) and disease-free survival (P = 0.005), but not metastasis-free survival. Mice treated with radiotherapy, but not anti-PD-1, showed significantly improved local recurrence-free survival and metastasis-free survival over surgery alone (P = 0.043 and P = 0.007, respectively). The overall metastasis rate was low (∼12%) in the p53/MCA sarcoma model, which limited the power to detect further improvement in metastasis-free survival with addition of anti-PD-1 therapy. Tail vein injections of sarcoma cells into immunocompetent mice suggested that impaired metastasis was due to inability of sarcoma cells to grow in the lungs rather than a consequence of immunosurveillance. In conclusion, neoadjuvant radiotherapy improves metastasis-free survival after surgery in a primary model of STS., (©2022 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
17. An investigation of kV mini-GRID spatially fractionated radiation therapy: dosimetry and preclinical trial.
- Author
-
Johnson TR, Bassil AM, Williams NT, Brundage S, Kent CL, Palmer G, Mowery YM, and Oldham M
- Subjects
- Animals, Dose Fractionation, Radiation, Mice, Mice, Inbred C57BL, Tumor Burden, Neoplasms radiotherapy, Radiometry
- Abstract
Objective . To develop and characterize novel methods of extreme spatially fractionated kV radiation therapy (including mini-GRID therapy) and to evaluate efficacy in the context of a pre-clinical mouse study. Approach . Spatially fractionated GRIDs were precision-milled from 3 mm thick lead sheets compatible with mounting on a 225 kVp small animal irradiator (X-Rad). Three pencil-beam GRIDs created arrays of 1 mm diameter beams, and three 'bar' GRIDs created 1 × 20 mm rectangular fields. GRIDs projected 20 × 20 mm
2 fields at isocenter, and beamlets were spaced at 1, 1.25, and 1.5 mm, respectively. Peak-to-valley ratios and dose distributions were evaluated with Gafchromic film. Syngeneic transplant tumors were induced by intramuscular injection of a soft tissue sarcoma cell line into the gastrocnemius muscle of C57BL/6 mice. Tumor-bearing mice were randomized to four groups: unirradiated control, conventional irradiation of entire tumor, GRID therapy, and hemi-irradiation (half-beam block, 50% tumor volume treated). All irradiated mice received a single fraction of 15 Gy. Results . High peak-to-valley ratios were achieved (bar GRIDs: 11.9 ± 0.9, 13.6 ± 0.4, 13.8 ± 0.5; pencil-beam GRIDs: 18.7 ± 0.6, 26.3 ± 1.5, 31.0 ± 3.3). Pencil-beam GRIDs could theoretically spare more intra-tumor immune cells than bar GRIDs, but they treat less tumor tissue (3%-4% versus 19%-23% area receiving 90% prescription, respectively). Bar GRID and hemi-irradiation treatments significantly delayed tumor growth ( P < 0.05), but not as much as a conventional treatment ( P < 0.001). No significant difference was found in tumor growth delay between GRID and hemi-irradiation. Significance . High peak-to-valley ratios were achieved with kV grids: two-to-five times higher than values reported in literature for MV grids. GRID irradiation and hemi-irradiation delayed tumor growth, but neither was as effective as conventional whole tumor uniform dose treatment. Single fraction GRID therapy could not initiate an anti-cancer immune response strong enough to match conventional RT outcomes, but follow-up studies will evaluate the combination of mini-GRID with immune checkpoint blockade., (© 2022 Institute of Physics and Engineering in Medicine.)- Published
- 2022
- Full Text
- View/download PDF
18. The Long Noncoding RNA NEAT1 Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways.
- Author
-
Huang J, Sachdeva M, Xu E, Robinson TJ, Luo L, Ma Y, Williams NT, Lopez O, Cervia LD, Yuan F, Qin X, Zhang D, Owzar K, Gokgoz N, Seto A, Okada T, Singer S, Andrulis IL, Wunder JS, Lazar AJ, Rubin BP, Pipho K, Mello SS, Giudice J, and Kirsch DG
- Subjects
- Humans, Neoplasm Metastasis, PC-3 Cells, Transfection, RNA Splicing genetics, RNA, Long Noncoding genetics, Sarcoma genetics
- Abstract
Soft-tissue sarcomas (STS) are rare malignancies showing lineage differentiation toward diverse mesenchymal tissues. Half of all high-grade STSs develop lung metastasis with a median survival of 15 months. Here, we used a genetically engineered mouse model that mimics undifferentiated pleomorphic sarcoma (UPS) to study the molecular mechanisms driving metastasis. High-grade sarcomas were generated with Cre recombinase technology using mice with conditional mutations in Kras and Trp53 (KP) genes. After amputation of the limb bearing the primary tumor, mice were followed for the development of lung metastasis. Using RNA-sequencing of matched primary KP tumors and lung metastases, we found that the long noncoding RNA (lncRNA) Nuclear Enriched Abundant Transcript 1 ( Neat1 ) is significantly upregulated in lung metastases. Furthermore, NEAT1 RNA ISH of human UPS showed that NEAT1 is upregulated within a subset of lung metastases compared with paired primary UPS. Remarkably, CRISPR/Cas9-mediated knockout of Neat1 suppressed the ability of KP tumor cells to colonize the lungs. To gain insight into the underlying mechanisms by which the lncRNA Neat1 promotes sarcoma metastasis, we pulled down Neat1 RNA and used mass spectrometry to identify interacting proteins. Interestingly, most Neat1 interacting proteins are involved in RNA splicing regulation. In particular, KH-Type Splicing Regulatory Protein (KHSRP) interacts with Neat1 and is associated with poor prognosis of human STS. Moreover, depletion of KHSRP suppressed the ability of KP tumor cells to colonize the lungs. Collectively, these results suggest that Neat1 and its interacting proteins, which regulate RNA splicing, are involved in mediating sarcoma metastasis. IMPLICATIONS: Understanding that lncRNA NEAT1 promotes sarcoma metastasis, at least in part, through interacting with the RNA splicing regulator KHSRP may translate into new therapeutic approaches for sarcoma., (©2020 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.